Zacks.com on MSN7h
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMSSanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
A breakthrough treatment is making a huge difference for stroke survivors, improving hand and arm function, and their quality ...
The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...
Kessler scientists' trial set to evaluate non-invasive brain stimulation for upper-extremity disability post-stroke, ...
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
A new study reveals how a single species of bacteria can sustain a diverse community of phage species, with implications for ...
The Irish News on MSN9d
Medical breakthrough as therapy unveiled for ‘untreatable’ debilitating illnessA man who does not wish to be named became the first person treated in the global trial a few weeks ago, receiving the ...
SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback